乳腺钼靶X射线摄片联合CA15-3、CA125、CEA、CYFRA21-1对乳腺癌的临床诊断价值分析

摘要/Abstract

摘要： 目的分析乳腺钼靶X射线摄片联合糖类抗原15-3（CA15-3）、糖类抗原125（CA125）、癌胚抗原（CEA）、细胞角蛋白19片段抗原21-1（CYFRA21-1）对乳腺癌（BC）的临床诊断价值。方法选取2023年5月—2024年1月赤峰市医院收治的78例BC患者为研究组,另选取80例乳腺良性病变患者为对照组。记录两组患者一般资料,用化学发光法测定肿瘤标志物（CA15-3、CA125、CEA、CYFRA21-1）水平,绘制受试者操作特征（ROC）曲线,用曲线下面积（AUC）分析单独使用上述肿瘤标志物、乳腺钼靶X射线摄片和两者联合运用的诊断价值。结果研究组血清CA15-3、CA125、CEA、CYFRA21-1水平高于对照组,差异有统计学意义（P<0.05）;CA15-3、CA125、CEA、CYFRA21-1与乳腺钼靶X射线摄片联合预测BC的敏感度为86.36%,特异度为84.21%,与单一指标相比联合诊断效能更高,差异有统计学意义（P<0.05）;ROC曲线分析结果显示：CA15-3、CA125、CEA、CYFRA21-1与乳腺钼靶X射线摄片联合预测BC的AUC为0.903,与单一指标相比联合诊断价值更高,差异有统计学意义（P<0.05）。结论 CA15-3、CA125、CEA、CYFRA21-1、乳腺钼靶X射线摄片对BC均具有良好的预测价值,两者联合预测效能更佳。

关键词: 乳腺癌, 乳腺钼靶X射线摄片, 肿瘤标志物

Abstract: Objective To analyze the clinical diagnostic value of X-ray combined with glycoantigen 15-3 (CA15-3), sugar antigen 125 (CA125), carcinoembryonic antigen (CEA), and cytokeratin 19 fragment antigen 21-1 (CYFRA21-1) in breast cancer (BC). Methods A total of 78 BC patients admitted to our hospital from May 2023 to January 2024 were selected as the study group, and another 80 patients with benign breast lesions were selected as the control group. Baseline data of both groups were recorded, the levels of tumor markers (CA15-3, CA125, CEA, CYFRA21-1) were determined by chemiluminescence, the working characteristics (ROC) curve was drawn, and the area under the curve (AUC) was used to analyze the diagnostic value of tumor markers and mammo X-ray photography alone and in combination. Results The serum CA15-3, CA125, CEA and CYFRA21-1 in the study group were higher than the control group, statistically different (P<0.05); ROC curve analysis showed that the AUC of tumor marker and mammo X-ray was 0.903, sensitivity of 86.36%, specificity of 84.21%, and higher predictive value than the single index, and the difference was statistically significant (P<0.05). Conclusion The level of CA15-3, CA125, CEA, CYFRA21-1 and mammography X-ray photography all have good predictive value for BC, and the combined prediction efficiency of both is better.

Key words: breast cancer, mammolybdenum X-ray, tumor marker

中图分类号:

R737.9

王欣. 乳腺钼靶X射线摄片联合CA15-3、CA125、CEA、CYFRA21-1对乳腺癌的临床诊断价值分析[J]. 中华养生保健, 2025, 43(5): 62-66.

WANG Xin. Analysis of the Clinical Diagnostic Value of Breast Molybdenum Target X-ray Photography Combined with CA15-3, CA125, CEA, and CYFRA21-1 in Breast Cancer[J]. ZHONGHUA YANGSHENG BAOJIAN, 2025, 43(5): 62-66.

参考文献

[1] 李博,全红,韩晶.外周血GP5、APC、GSTP1基因甲基化联合检测与乳腺癌相关性的研究[J].同济大学学报(医学版),2023,44(3):417-424.
[2] 郭奕阳,马伟丽,曹诗茹,等.血清外泌体Glypican-1在乳腺癌中的表达水平及临床应用价值[J].河北医科大学学报,2022,43(10):1183-1187.
[3] MA J.Application value of digital tungsten-molybdenum dual target three-dimensional positioning indwelling guide wire excision biopsy in diagnosis of breast microcalcification[J].Journal of X-ray science and technology,2023,31(4):853-864.
[4] 王海霞,宋倩,郑国红,等.钼靶和超声多普勒结合血清肿瘤标志物诊断早期乳腺癌研究[J].中国医学装备,2024,21(1):82-87.
[5] 中国抗癌协会乳腺癌专业委员会.中国抗癌协会乳腺癌诊治指南与规范(2021年版)[J].中国癌症杂志,2021,31(10):954-1040.
[6] 沈怡媛,尤超,蔺璐奕,等.MRI及临床病理特征对乳腺癌人表皮生长因子受体2表达状态的鉴别诊断价值[J].磁共振成像,2024,15(1):6-13.
[7] 周雅筠,谢瑾,张蓓,等.常规超声、超声造影、钼靶X线、磁共振成像及联合检测对早期乳腺癌患者的诊断价值[J].贵州医科大学学报,2023,48(2):172-176.
[8] 宋鹏杰,王艳蕾,孙晨,等.基于真实世界数据的乳腺超声人工智能诊断和X射线钼靶摄影检查在早期乳腺癌筛查中的对比研究[J].中国医学装备,2023,20(9):20-24.
[9] 张静,姜雨萌,许傲迪,等.18F-FDG PET/CT联合肿瘤标志物在乳腺癌并发第二原发肺癌中的诊断及鉴别诊断价值[J].临床放射学杂志,2024,43(2):223-230.
[10] 杨大才,陈鹤,彭良琴,等.彩色多普勒超声联合CYFRA21-1、sTNFR-P55及HE4检测在乳腺癌早期诊断中的应用[J].分子诊断与治疗杂志,2022,14(9):1574-1577.
[11] 张维,龙松权,唐瑞骏.不同分子分型乳腺癌血清CYFRA21-1、HCY和CA15-3的表达差异及与术后复发、转移的关系[J].检验医学与临床,2023,20(12):1686-1689.
[12] 刘雪玲,李青,许永潜,等.ALP、肿瘤标志物和免疫炎症指标对乳腺癌骨转移的预测价值[J].暨南大学学报(自然科学与医学版),2023,44(6):592-601.
[13] 何瑞红,李立,钱伟军.DCE-MRI、多b值DWI结合CA153、CEA对乳腺癌及肿块型浆细胞性乳腺炎的鉴别诊断价值研究[J].中国CT和MRI杂志,2023,21(6):89-92.
[14] 翟耀君,万东民,褚瑞军,等.ABCG2基因多态性联合血清CA153、CEA预测乳腺癌术后复发的价值[J].临床和实验医学杂志,2022,21(19):2080-2084.
[15] 于博凡,于洋,申鹏,等.不同分子分型乳腺癌患者血清肿瘤标志物癌胚抗原、糖类抗原125、糖类抗原15-3的表达及与复发转移的关系[J].中国卫生检验杂志,2022,32(14):1726-1729.